**DVN: Explanation on the combined profit after tax in 2023 compared to 2022**

On March 28, 2024, Viet Nam Pharmaceutical Corporation - Joint Stock Company announced Official Dispatch No. 105/TCTD-TCKT on explaining the combined profit after tax in 2023 changing compared to 2022 as follows:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| No. | Targets | In 2023 (VND) | In 2022 (VND) | Difference |
| Amount (VND) | Rate |
| (1) | (2) | (3) | (4) | (5)=(3)-(4) | (6)=(5)/(4) |
|  | Combined profit after tax | 222,800,078,273 | 27,579,662,892 | 195,220,415,381 | 707.84% |

The main reasons leading to the difference in combined profit after tax compared to the same period last year of the Corporation:

* Financial expenses in 2023 decreased compared to 2022: Due to share price fluctuations of a number of companies with investment capital of the Corporation on the stock exchange, the Corporation's expenses for provisioning for financial investment losses in 2023 are lower than those in 2022.
* Revenue from financial activities (dividends) in 2023 is higher than in 2022: The recognition of revenue from dividends depends on each unit's annual dividend payment plan. In 2023, some units with contributed capital of the Corporation paid higher dividends than in 2022.